Informace o publikaci

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Autoři	GROSICKI Sebastian SIMONOVA Maryana SPICKA Ivan POUR Luděk KRIACHOK Iryrna GAVRIATOPOULOU Maria PYLYPENKO Halyna AUNER Holger W LELEU Xavier DORONIN Vadim USENKO Ganna BAHLIS Nizar J HAJEK Roman BENJAMIN Reuben DOLAI Tuphan K SINHA Dinesh K VENNER Christopher P GARG Mamta GIRONELLA Mercedes JURCZYSZYN Artur ROBAK Pawel GALLI Monica WALLINGTON-BEDDOE Craig RADINOFF Atanas SALOGUB Galina DON STEVENS BASU Supratik LIBERATI Anna M QUACH Hang GORANOVA-MARINOVA Vesselina S BILA Jelena KATODRITOU Eirini OLIYNYK Hanna KORENKOVA Sybiryna KUMAR Jeevan JAGANNATH Sundar MOREAU Phillipe LEVY Moshe WHITE Darrell GATT Moshe E FACON Thierry MATEOS Maria V CAVO Michele REECE Donna JR Larry D Anderson SAINT-MARTIN Jean-Richard JEHA Jacqueline ANITA JOSHI CHAI Yi LI Lingling PEDDAGALI Vishnuvardhan ARAZY Melina SHAH Jatin SHACHAM Sharon KAUFFMAN Michael G MELETIOS DIMOPOULOS RICHARDSON Paul G DELIMPASI Sosana
Rok publikování	2020
Druh	Článek v odborném periodiku
Časopis / Zdroj	Lancet
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://www.sciencedirect.com/science/article/pii/S0140673620322923?via%3Dihub
Doi	http://dx.doi.org/10.1016/S0140-6736(20)32292-3
Popis	Selinexor combined with dexamethasone has shown activity in patients with heavily pre-treated multiple myeloma. In a phase 1b/2 study, the combination of oral selinexor with bortezomib (a proteasome inhibitor) and dexamethasone induced high response rates with low rates of peripheral neuropathy, the main dose-limiting toxicity of bortezomib. We aimed to evaluate the clinical benefit of weekly selinexor, bortezomib, and dexamethasone versus standard bortezomib and dexamethasone in patients with previously treated multiple myeloma.